Homepage | Lupus Science & Medicine
Lupus Science & Medicine® is a global, peer reviewed, open access online journal that provides a central point for publication of basic, clinical, translational, and epidemiological studies of all aspects of lupus and related diseases. An official journal of the Lupus Foundation of America (LFA), which is dedicated to advancing the science and medicine of lupus while offering support to ...
Effects of systemic lupus erythematosus on the brain: a systematic ...
Background Cognitive dysfunction (CD) is highly prevalent in systemic lupus erythematosus (SLE), yet the underlying mechanisms are poorly understood. Neuroimaging utilising advanced MRI metrics may yield mechanistic insights. We conducted a systematic review of neuroimaging studies to investigate the relationship between structural and diffusion MRI metrics and CD in SLE. Methods We ...
Clinical implications of discordance between anti-dsDNA …
Objective Anti-dsDNA antibodies (anti-dsDNA) are a component of all classification schemes in SLE and comprise one of the domains in validated activity indices. Anti-dsDNA is frequently measured commercially by an enzyme immunoassay (EIA) or Crithidia luciliae immunofluorescence test (CLIFT). To address the clinical impact of measuring these antibodies by two different assays, this study ...
Clinical trial outcomes for SLE: what we have and what we need
The paradigm of drug approval in SLE currently relies on successful large phase III randomised controlled trials and a set of primary, secondary and additional end points. Taken together, these outcomes offer a nuanced understanding of the efficacy and safety of the investigational agent. In this review, we thoroughly examine the main outcomes used in SLE trials and highlight unmet ...
Thanoua etΔal Lupus Science Medicine 216e365 doi11136lupus21365 1 Scoring systemic lupus erythematosus (SLE) disease activity with simple, rapid outcome measures Aikaterini Thanou , 1 Judith A James,1,2 Cristina Arriens , 1 Teresa Aberle,1 Eliza Chakravarty,1 Joseph Rawdon,1 Stavros Stavrakis,2 Joan T Merrill,1 Anca Askanase3 To cite: Thanou A, James JA, ...
Therapy with direct oral anticoagulants for secondary prevention …
Objective Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterised by venous thrombosis (VT) or arterial thrombosis (AT) and/or pregnancy morbidity and the presence of antiphospholipid antibodies. Direct oral anticoagulants (DOACs) hold several advantages to vitamin K antagonists (VKAs) for prevention of thrombosis and we wish to evaluate DOACs compared with VKAs in ...
Which outcome measures in SLE clinical trials best reflect medical ...
Objectives To compare two measures of systemic lupus erythematosus (SLE) response: the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) and the Systemic Lupus Responder Index (SRI) against a clinician's assessment of improvement. Methods Ninety-one lupus patients were identified with two visits at which Systemic Lupus Erythematosus Disease Activity Index ...
SARS-CoV-2 vaccines in patients with SLE - Lupus Science
As the Moderna (mRNA-1273) and Pfizer/BioNTech (BNT162b2) vaccines become available to patients with autoimmune diseases and SLE, practitioners will have to inform them about the safety and efficacy of these vaccines. Here we discuss the challenges of applying vaccine data to patients with autoimmune diseases and the evidence available in the literature that may help in the decision process.
van VollenhovenflRF, etfial Lupus Science Medicine 20218e000538 doi101136lupus-2021-000538 1 2021 DORIS definition of remission in SLE: final recommendations from an international task force Ronald F van Vollenhoven ,1 George Bertsias,2 Andrea Doria ,3 David Isenberg,4 Eric Morand ,5 Michelle A Petri ,6 Bernardo A Pons-Estel ,7 Anisur Rahman,8 Manuel Francisco Ugarte-Gil ,9,10
Hydroxychloroquine daily dose, hydroxychloroquine blood levels …
Background Recent guidelines for SLE recommend using a hydroxychloroquine (HCQ) dose less than 5.0 mg/kg/day to reduce the risk of retinopathy. To determine if this dose reduction would have an impact on the clinical course of SLE, we compared flare incidence in a cohort of patients with SLE treated with two different oral HCQ dosages (≤5 mg/kg/day or >5 mg/kg/day).